Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Amgen Inc. > News item |
Jefferies puts Amgen on hold
Amgen, Inc. was rated at hold by Jefferies & Co., Inc. analyst Adam Walsh on the expected approval of Vectibix in third-line metastatic colorectal cancer (mCRC). The company is running trials with Vectibix in first-line and second-line mCRC and other cancer indications. Shares of the Thousand Oaks, Calif.-based biotechnology company were down 59 cents, or 0.82%, at $71.55. (Nasdaq: AMGN)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.